Trial Parameters
Brief Summary
Myelofibrosis (MF) is a myeloproliferative neoplasm causing bone marrow failure and high risk of leukemia transformation. JAK2 inhibitors improve symptoms but do not cure MF. Allogeneic stem cell transplantation (allo-HSCT) is the only potential cure, though limited donor availability restricts access. Haploidentical transplantation shows promise but associated with higher graft failure and treatment related mortality. We recently developed a novel regimen of haplo-SCT for MF. This study aims to investigate this novel protocol in a prospective trial to improve MF outcomes.
Eligibility Criteria
Inclusion Criteria: * Primary disease type: Myelofibrosis (including primary myelofibrosis and myelofibrosis secondary to polycythemia vera or essential thrombocythemia). * No matched sibling donor or unrelated donor, with the availability of a haploidentical donor. * Signed informed consent. Exclusion Criteria: 1. Active infection 2. Very poor performance status (ECOG score \> 2) 3. Estimated survival time \< 30 days 4. Patient or family unable to cooperate 5. Considered unsuitable after discussion